Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Neurorestorative Treatment Strategies Hold Promise for Most Severe Forms of Epilepsy

By HospiMedica International staff writers
Posted on 08 Apr 2025

Epilepsy affects approximately 50 million people worldwide, with around 30% of these individuals, or roughly 15 million people, suffering from drug-resistant epilepsy (DRE). More...

While some patients experience only a few seizures per month, others may have hundreds of seizures each day, ranging from mild episodes to life-threatening events. Current treatment options for DRE include surgical interventions like brain resection, where a portion of the brain tissue responsible for seizures is removed. Another approach is laser ablation therapy, which targets and destroys abnormal brain tissue using focused energy. Although these surgical methods can be effective, they carry the risk of side effects such as memory problems, motor deficits, and speech difficulties. Another surgical option, neuromodulation, uses electrical or magnetic stimulation to interrupt abnormal brain activity without removing brain tissue. However, a new and innovative trend in research is exploring the use of regenerative medicine as a "reparative" approach to help heal the brain in patients with DRE.

Researchers at Mayo Clinic (Rochester, MN, USA) are conducting the first-in-human clinical trial to evaluate the use of specialized inhibitory brain cells implanted as a potential reparative treatment for DRE. This minimally invasive technique involves injecting these inhibitory cells through a small, pencil eraser-sized incision at the back of the head. The goal is for these cells to integrate into the brain over time, helping to repair the neural circuitry and reducing or preventing seizures without causing the side effects associated with traditional surgical methods. Mayo Clinic's Arizona location is one of 29 sites nationwide taking part in this trial, which focuses on patients with focal epilepsy, where seizures are localized to a specific brain region.

At Mayo Clinic in Florida, another clinical trial is exploring the potential of regenerative medicine as a reparative treatment for DRE. This trial is investigating the combination of implanted stem cells and neuromodulation therapy. One of the most recent FDA-approved neuromodulation therapies for epilepsy is deep brain stimulation (DBS). While DBS has been shown to reduce seizures by up to 70% after five years, it is rare for patients to become completely seizure-free. To address this, researchers are combining DBS with stem cell therapy in hopes of enhancing the effectiveness of neuromodulation. This clinical trial involves implanting adipose-derived mesenchymal stem cells (MSCs), a type of adult stem cell with anti-inflammatory properties that may aid in healing, as an adjunct to DBS for patients with DRE.

"We've thought about this for generations, we just didn't have these technologies to enable it. Now we do," said Sanjeet Grewal, M.D., director of stereotactic and functional neurosurgery at Mayo Clinic. "So, whether it's wound healing, neurodegeneration, epilepsy or stroke, there are so many different studies going on investigating the potential of regenerative or reparative therapies."

Related Links:
Mayo Clinic


Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.